Arginine, Ornithine, Lysine Capsules
Natural health product licensed in Canada
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| L-Lysine Source : Monochlorhydrate de L-lysine | 150 milligramme | Not calculated |
| Acide (S)-2,5-diaminopentanoïque Source : L-Ornithine Hydrochloride | 150 milligramme | Not calculated |
Non-medicinal ingredients
Gélatine, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Capsule | 2 Tous les jours |
Uses authorised in Canada
L-Arginine is a non-essential amino acid that is involved in protein synthesis. Lysine is an essential amino acid for the maintenance of good health. Helps in collagen formation.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Do not use if you have had a heart attack/myocardial infarction.
- Effets indésirables connus
Some people may experience gastrointestinal discomfort (such as diarrhea). May cause nausea, vomiting, and bloating.
- Précautions et mises en garde
Consult a health care practitioner prior to use if you are pregnant or breastfeeding. Consult a health care practitioner if your cardiovascular condition worsens. Consult a health care practitioner prior to use if you have a renal/kidney disease or if you are following a low protein diet. Consult a health care practitioner prior to use if you suffer from a cardiovascular disease and are attempting an increase in physical activity. Consult a health care practitioner prior to use if you are taking medication for cardiovascular diseases, erectile dysfunction, and/or blood thinners.
Product record
- Other names
- Amino Triple Action, Arginine, Ornithine, Lysine, Tri-Amino
- Licence holder
- Vitaminol Inc.
- NPN or DIN-HM
- 80040091
- Status
- Active licence
- Licence date
- 19 February 2013
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
Source
Official Health Canada record, licence 80040091
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Arginine, Ornithine, Lysine Capsules”, https://compoatlas.com/en/supplements/canada/80040091-arginine-ornithine-lysine-capsules, updated 19 February 2013.